Develops psilocybin-based therapies for treatment-resistant depression and other mental health conditions.
COMPASS Pathways plc is a leading mental health care company with operations centered in the United Kingdom and the United States. The company specializes in developing innovative therapies, notably COMP360, a pioneering psilocybin therapy. COMP360 has successfully completed Phase IIb clinical trials targeting treatment-resistant depression and is currently advancing through Phase II trials for post-traumatic stress disorder (PTSD).
Founded in 2020 and originally known as COMPASS Rx Limited, the company rebranded as COMPASS Pathways plc in August 2020 to reflect its strategic focus and expansion in the mental health care sector. Headquartered in London, UK, COMPASS Pathways plc is at the forefront of exploring the therapeutic potential of psychedelic compounds to address profound unmet needs in mental health treatment.
Driven by a commitment to innovation and patient-centric care, COMPASS Pathways plc continues to push the boundaries of psychedelic medicine research. With a dedicated team and a visionary approach, the company aims to pave the way for new standards in mental health care through its transformative therapies and ongoing clinical advancements.